Comprehensive research overview of ACE-031, a myostatin inhibitor peptide: mechanism, preclinical studies, clinical trial results, safety profile, and regulatory status. Evidence-based.
# ACE-031: Myostatin Inhibitor Research Overview
Comprehensive research overview of ACE-031, a myostatin inhibitor peptide: mechanism, preclinical studies, clinical trial results, safety profile, and regulatory status. Evidence-based.
Data-driven content targeting the keyword cluster "ace-031" with 1 related keywords and 0 monthly search volume.
Define ACE-031 as a modified activin receptor type IIB ActRIIB fusion protein that inhibits myostatin and related ligands. Briefly mention its development by Acceleron Pharma and its investigational status. Emphasize research-only context.
Explain the myostatin/TGF-β pathway. Describe how ACE-031 acts as a decoy receptor, sequestering myostatin, GDF11, and activins. Detail resulting increases in muscle mass and bone density observed in animal models. Avoid oversimplification; cite relevant studies.
Summarize key preclinical trials with mice and non-human primates. Report increases in lean body mass, grip strength, and bone mineral density. Note any observed adverse effects e.g., reproductive/nasal bleeding in primates . Use quantitative data where available.
Describe phase 1 single ascending dose and multiple ascending dose studies in healthy volunteers. Report notable adverse events e.g., nosebleeds, gum bleeding, telangiectasias . Explain why development was halted after phase 2 due to vascular adverse effects. Keep neutral, factual tone.
List documented side effects from clinical trials: epistaxis, telangiectasias, gingival bleeding. Discuss potential risks related to off-label use. Clearly state that ACE-031 is not FDA-approved for any indication and is only for research. Include standard safety caveat.
Briefly compare mechanism, route SC vs IV , clinical stage, and safety profiles with other myostatin inhibitors. Avoid direct dosing comparisons. Position ACE-031 within the broader peptide landscape for muscle growth.
Answer these concisely based on available evidence. For legality: discuss research chemical status, not for human use. Half-life: cite about 12-15 days from studies. Stacking: note lack of human data but theoretical interactions – discourage speculation.
1. BPC-157 for tissue repair https://peptideatlas.co/peptides/bpc-157 , Peptide Atlas.
2. TB-500 for muscle recovery https://peptideatlas.co/peptides/tb-500 , Peptide Atlas.
3. Semaglutide for metabolic health https://peptideatlas.co/peptides/semaglutide , Peptide Atlas.
4. Tirzepatide dual agonist https://peptideatlas.co/peptides/tirzepatide , Peptide Atlas.
5. PT-141 for sexual health https://peptideatlas.co/peptides/pt-141 , Peptide Atlas.
6. Ipamorelin growth hormone secretagogue https://peptideatlas.co/peptides/ipamorelin , Peptide Atlas.
7. CJC-1295 GHRH analog https://peptideatlas.co/peptides/cjc-1295 , Peptide Atlas.
8. GHK-Cu for regeneration https://peptideatlas.co/peptides/ghk-cu , Peptide Atlas.
9. Melanotan II for tanning https://peptideatlas.co/peptides/melanotan-ii , Peptide Atlas.
10. LL-37 antimicrobial peptide https://peptideatlas.co/peptides/ll-37 , Peptide Atlas.
This resource is for education and research context only. It does not provide medical advice, diagnosis, treatment instructions, personal dosing guidance, or vendor recommendations.